Companies and Partnerships

 

  • Revolv was established in September 2009 as a wholly owned subsidiary of Corvesta, Inc. Revolv is a dental benefits administration and health informatics company providing specialized customer services and advanced claims processing systems with fast and accurate claims adjudication capabilities, as well as ancillary services such as benefits consultation, business analytics, quality assessment and integrity tools–all specifically designed to address the unique needs and regulatory landscape of the dental insurance marketplace. To learn more, visit www.myrevolv.com.

  • Corvesta Life Insurance Company became a member of the Corvesta Enterprise in 2011. Corvesta Life has secured licenses to sell insurance in 45 states and the District of Columbia. Corvesta Life will use these licenses to focus on writing dental, health and life insurance, which falls in their core area of expertise.

  • Corvesta has invested in Encara, which was formed to serve the dental benefits marketplace for individuals. Encara has built out an efficient lead-generation, customer-acquisition and member-servicing engine. Encara also develops market-leading individual dental products.

  • Healthentic is an oral health disease management and dental analytics company formed in 2008. They offer products and services to employer groups that allow benefit managers to gain visibility into their populations’ oral health and compare it directly against peers by industry and size. Employers can see one overall score for their population and review oral healthsegmentation to understand what percent of their population is considered healthy vs. moderate or serious. If desired, medical and pharmacy data can also be incorporated into the analysis for a more complete picture of overall health and to serve as a basis for disease management programs. To learn more, visit www.healthentic.com.

  • Corvesta is an investor in C3 Jian, Inc., a biotech company that creates unique products that diagnose, treat and prevent bacterial and fungal infections in humans, animals and plants. The initial focus is the eradication of the bacteria that cause cavities and periodontal diseases and antimicrobial therapies for medical microbial pathogens on mucosal surfaces. This partnership may result in innovative dental treatments and product plan designs in the future. To learn more, visit www.c3-jian.com.